Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Theralase Technologies Inc (OP:TLTFF)

0.2010 -0.0225 (-10.07%)
Streaming Delayed Price Updated: 11:25 AM EDT, May 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theralase Technologies Inc

< Previous 1 2 3 4 Next >
News headline image
Theralase Discovers New Mechanism of Action of Lead Drug
Toronto, Ontario--(Newsfile Corp. - April 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
News headline image
Theralase(R) Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
News headline image
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
Via Newsfile
News headline image
Ruvidar Demonstrates 7 Year Complete Response
Toronto, Ontario--(Newsfile Corp. - April 7, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical... 
Via Newsfile
News headline image
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
News headline image
Theralase(R) Launches New Clinical Study Site in Canada
Via ACCESSWIRE
News headline image
Ruvidar Effective in the Treatment of Herpes
Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
News headline image
Theralase(R) Releases 2024 Annual Financial Statements
Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
News headline image
Theralase(R) Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 11, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
News headline image
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
Toronto, Ontario--(Newsfile Corp. - March 10, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a... 
Via Newsfile
News headline image
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
Toronto, Ontario--(Newsfile Corp. - February 25, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical... 
Via Newsfile
Topics Death
News headline image
Theralase(R) Demonstrates Effective Treatment of Herpes
Via ACCESS Newswire
News headline image
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
Via ACCESS Newswire
News headline image
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
Via ACCESS Newswire
News headline image
Theralase(R) Launches Three New Clinical Study Sites in USA
Via ACCESSWIRE
News headline image
Theralase(R) Release’s 3Q2024 Financial Statements
Via ACCESSWIRE
News headline image
Theralase(R) Closes Non-Brokered Private Placement
Via ACCESSWIRE
News headline image
Theralase(R) Extends Warrants
Via ACCESSWIRE
News headline image
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Via ACCESSWIRE
News headline image
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
Via ACCESSWIRE
News headline image
Theralase(R) Extends Warrants
Via ACCESSWIRE
News headline image
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
Via ACCESSWIRE
News headline image
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
Via ACCESSWIRE
News headline image
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
Via ACCESSWIRE
News headline image
Theralase(R) Release’s 2Q2024 Financial Statements
Via ACCESSWIRE
News headline image
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
Via ACCESSWIRE
News headline image
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
Via ACCESSWIRE
News headline image
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
Via ACCESSWIRE
News headline image
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
Via ACCESSWIRE
News headline image
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.